SI2718320T1 - Molekule, ki vežejo anti-Pseudomonas psl in njihova uporaba - Google Patents

Molekule, ki vežejo anti-Pseudomonas psl in njihova uporaba Download PDF

Info

Publication number
SI2718320T1
SI2718320T1 SI201231259T SI201231259T SI2718320T1 SI 2718320 T1 SI2718320 T1 SI 2718320T1 SI 201231259 T SI201231259 T SI 201231259T SI 201231259 T SI201231259 T SI 201231259T SI 2718320 T1 SI2718320 T1 SI 2718320T1
Authority
SI
Slovenia
Prior art keywords
seq
antibody
infection
chain variable
variable region
Prior art date
Application number
SI201231259T
Other languages
English (en)
Inventor
Antonio Digiandomenico
Paul G. Warrener
Charles K. Stover
Bret Sellman
Sandrine Guillard
Ralph Minter
Steven Rust
Mladen Tomich
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of SI2718320T1 publication Critical patent/SI2718320T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

  1. Molekule, ki vežejo anti-Pseudomonas psi in njihova uporaba Patentni zahtevki
    1. Monoklonsko protitelo, ki se veže specifično na Pseudomonas Psi eksopolisaharid, kjer protitelo spodbuja opsonofagocitno ubijanje (opsonophagocytic killing (OPK)) P. aeruginosa, neobvezno, kjer protitelo zavira vezavo P. aeruginosa na epitelijske celice.
  2. 2. Protitelo po zahtevku 1, ki konkurenčno zavira vezavo Pseudomonas Psi eksopolisaharida s protitelesom ali njegovim vezivnim delcem, ki vsebuje variabilno regijo težke verige (VH) in variabilno regijo lahke verige (VL) izbrani iz skupine, ki vsebuje: SEQ ID NO: 1 in SEQ ID NO: 2 (Cam-003), SEQ ID NO: 3 in SEQ ID NO: 2 (Cam-004), SEQ ID NO: 4 in SEQ ID NO: 2 (Cam-005), SEQ ID NO: 5 in SEQ ID NO: 6 (WapR-001), SEQ ID NO: 7 in SEQ ID NO: 8 (WapR-002), SEQ ID NO: 9 in SEQ ID NO: 10 (WapR-003), SEQ ID NO: 11 in SEQ ID NO: 12 (WapR-004), SEQ ID NO: 74 in SEQ ID NO: 12 (WapR-004RAD) in SEQ ID NO: 15 in SEQ ID NO: 16 (WapR-016).
  3. 3. Protitelo po zahtevku 1, ki vsebuje variabilno regijo težke verige (VH) in variabilno regijo lahke verige (VL), ki imata zaporedja mino kislin vsaj 90% enaka z VH in VL izbranimi iz skupine, ki vsebuje: (a) SEQ ID NO: 1 in SEQ ID NO: 2, (b) SEQ ID NO: 3 in SEQ ID NO: 2, (c) SEQ ID NO: 4 in SEQ ID NO: 2, (d) SEQ ID NO: 5 in SEQ ID NO: 6, (e) SEQ ID NO: 7 in SEQ ID NO: 8, (f) SEQ ID NO: 9 in SEQ ID NO: 10, (g) SEQ ID NO: 11 in SEQ ID NO: 12, (h) SEQ ID NO: 74 in SEQ ID NO: 12; in 0) SEQ ID NO: 15 in SEQ ID NO: 16, ki neobvezno vsebuje variabilno regijo težke verige (VH) in variabilno regijo lahke verige (VL), ki imata zaporedje amino kislin izbrano iz skupine, ki vsebuje: (a) SEQ ID NO: 1 in SEQ ID NO: 2, (b) SEQ ID NO: 3 in SEQ ID NO: 2, (c) SEQ ID NO: 4 in SEQ ID NO: 2, (d) SEQ ID NO: 5 in SEQ ID NO: 6, (e) SEQ ID NO: 7 in SEQ ID NO: 8, (f) SEQ ID NO: 9 in SEQ ID NO: 10, (g) SEQ ID NO: 11 in SEQ ID NO: 12, (h) SEQ ID NO: 74 in SEQ ID NO: 12; in 0) SEQ ID NO: 15 in SEQ ID NO: 16.
  4. 4. Protitelo po zahtevku 1, ki vsebuje variabilno regijo težke verige (VH) in variabilno regijo lahke verige (VL), ki vsebuje VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 in VLCDR3, ki imajo zaporedja amino kislin enaka: SEQ ID NO: 17, 18, 19, 20, 21 in 22, SEQ ID NO: 23, 24, 25, 20, 21 in 22, SEQ ID NO: 26, 27, 28, 20, 21 in 22, SEQ ID NO: 29, 30, 31, 32, 33 in 34, SEQ ID NO: 35, 36, 37, 38, 39 in 40, SEQ ID NO: 41, 42, 43, 44, 45 in 46, SEQ ID NO: 47, 48, 49, 50, 51 in 52, SEQ ID NO: 47,48, 75, 50, 51 in 52, ali SEQ ID NO: 59, 60, 61, 62, 63 in 64.
  5. 5. Protitelo po kateremkoli zahtevku od 1 do 4, kije humanizirano, himerno ali popolnoma humano.
  6. 6. Sestavek, ki vsebuje protitelo po kateremkoli zahtevku od 1 do 5 in nosilec.
  7. 7. Izoliran polinukleotid, ki kodira protitelo po kateremkoli zahtevku od 1 do 5.
  8. 8. Vektor, ki vsebuje polinukleotid po zahtevku 7.
  9. 9. Gostiteljska celica, ki vsebuje polinukleotid po zahtevku 7 ali vektor po zahtevku 8.
  10. 10. Postopek izdelave protitelesa, ki obsega kultiviranje gostiteljske celice, ki vsebuje polinukleotid po zahtevku 7 in pridobivanje protitelesa.
  11. 11. Izolirano protitelo proizvedeno po postopku po zahtevku 10.
  12. 12. Protitelo po kateremkoli zahtevku od 1 do 5 in 11 ali sestavek po zahtevku 6 za uporabo v preventivi ali zdravljenju okužbe s Pseudomonas v subjektu, ki ga potrebuje, neobvezno, kjer je okužba s Pseudomonas okužba s P. aeruginosa, neobvezno, kjer je subjekt človek, neobvezno, kjer je okužba očesna okužba, pljučna okužba, okužba opekline, okužba rane, kožna okužba, okužba krvi, kostna okužba ali kombinacija dveh ali več omenjenih okužb.
  13. 13. Protitelo po kateremkoli zahtevku od 1 do 5 in 11 ali sestavek po zahtevku 6 za uporabo v preprečevanju ali preventivi vezave P. aeruginosa na epitelijske celice, kjer je mešanica epitelijskih celic in P. aeruginosa kontaktirana s protitelesom ali s sestavkom.
  14. 14. Protitelo po kateremkoli zahtevku od 1 do 5 in 11 ali sestavek po zahtevku 6 za uporabo v spodbujanju OPK P. aeruginosa, kjer je mešanica fagocitnih celic in P. aeruginosa kontaktirana s protitelesom ali s sestavkom, neobvezno, kjer se fagocitne celice razlikujejo od celic HL-60 ali humanih polimorfonuklearnih levkocitov (PMN).
SI201231259T 2011-06-10 2012-06-08 Molekule, ki vežejo anti-Pseudomonas psl in njihova uporaba SI2718320T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495460P 2011-06-10 2011-06-10
US201161530461P 2011-09-02 2011-09-02
US201261613317P 2012-03-20 2012-03-20
EP12796646.3A EP2718320B1 (en) 2011-06-10 2012-06-08 Anti-pseudomonas psl binding molecules and uses thereof
PCT/US2012/041538 WO2012170807A2 (en) 2011-06-10 2012-06-08 Anti-pseudomonas psl binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
SI2718320T1 true SI2718320T1 (sl) 2018-06-29

Family

ID=47296761

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231259T SI2718320T1 (sl) 2011-06-10 2012-06-08 Molekule, ki vežejo anti-Pseudomonas psl in njihova uporaba

Country Status (22)

Country Link
US (4) US9403901B2 (sl)
EP (2) EP3385280A1 (sl)
JP (2) JP6058645B2 (sl)
KR (1) KR102111171B1 (sl)
CN (1) CN103974975B (sl)
AU (3) AU2012267732A1 (sl)
BR (1) BR112013031485B1 (sl)
CA (1) CA2838211C (sl)
CY (1) CY1120557T1 (sl)
DK (1) DK2718320T3 (sl)
ES (1) ES2664972T3 (sl)
HK (1) HK1257190A1 (sl)
HR (1) HRP20180458T1 (sl)
HU (1) HUE038509T2 (sl)
LT (1) LT2718320T (sl)
MX (1) MX349886B (sl)
PL (1) PL2718320T3 (sl)
PT (1) PT2718320T (sl)
RS (1) RS57024B1 (sl)
RU (2) RU2708977C2 (sl)
SI (1) SI2718320T1 (sl)
WO (1) WO2012170807A2 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
LT2776065T (lt) 2011-11-07 2020-10-12 Medimmune Limited Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules
CA2888211A1 (en) * 2012-11-06 2014-05-15 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
JP2016524606A (ja) * 2013-05-14 2016-08-18 メディミューン，エルエルシー 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＰｓｌエキソ多糖の合成オリゴ糖サブユニットおよびその使用
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
JP7110095B2 (ja) 2015-11-30 2022-08-01 メドイミューン・リミテッド 院内肺炎を予防または治療する方法
DK3365368T3 (da) 2016-03-11 2023-06-26 Scholar Rock Inc Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
EP3452090A4 (en) * 2016-05-05 2019-12-18 The Trustees of The University of Pennsylvania CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST PSEUDOMONAS AERUGINOSA
CN110475829B (zh) 2017-04-03 2022-09-20 富士胶片株式会社 油墨组合物及其制造方法、以及图像形成方法
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
AU2020223205A1 (en) 2019-02-12 2021-08-05 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP7474393B2 (ja) 2020-04-22 2024-04-25 センクシア株式会社 アンカーボルトの施工方法、及びその方法に使用する箱抜き用型枠
WO2022028444A1 (en) * 2020-08-07 2022-02-10 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas psl and uses thereof
WO2024123712A1 (en) * 2022-12-04 2024-06-13 Genentech, Inc. Analysis of candidate cytotoxic compositions

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3685700T2 (de) * 1985-03-11 1993-03-11 Teijin Ltd E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
WO2002102855A2 (en) 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US7119172B2 (en) * 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030232387A1 (en) 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
NZ586357A (en) * 2007-11-30 2012-10-26 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
CA2711863C (en) 2008-01-10 2014-06-10 Shionogi & Co., Ltd. Antibody directed against pcrv
WO2009092011A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
CA2742791A1 (en) 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010091189A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2010107778A1 (en) 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2417157A1 (en) * 2009-04-09 2012-02-15 Kenta Biotech AG Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
CA2784033A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CA2826566C (en) 2011-02-08 2022-09-13 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
WO2013070565A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
LT2776065T (lt) 2011-11-07 2020-10-12 Medimmune Limited Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules
CA2888211A1 (en) 2012-11-06 2014-05-15 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
AU2013341361A1 (en) 2012-11-06 2015-06-04 Medimmune, Llc Antibodies to S. aureus surface determinants
ES2912267T3 (es) 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
JP2016524606A (ja) * 2013-05-14 2016-08-18 メディミューン，エルエルシー 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＰｓｌエキソ多糖の合成オリゴ糖サブユニットおよびその使用
EP3139950A4 (en) 2014-05-05 2017-12-20 Medimmune, LLC Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
JP7110095B2 (ja) 2015-11-30 2022-08-01 メドイミューン・リミテッド 院内肺炎を予防または治療する方法
EP3452090A4 (en) 2016-05-05 2019-12-18 The Trustees of The University of Pennsylvania CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST PSEUDOMONAS AERUGINOSA
JP6988094B2 (ja) 2017-01-27 2022-01-05 富士フイルムビジネスイノベーション株式会社 ポリイミド前駆体組成物、及びポリイミド成形体の製造方法

Also Published As

Publication number Publication date
WO2012170807A3 (en) 2013-03-28
CN103974975B (zh) 2018-06-29
DK2718320T3 (en) 2018-03-26
MX2013014372A (es) 2014-08-21
EP2718320A2 (en) 2014-04-16
BR112013031485A2 (pt) 2016-11-22
EP3385280A1 (en) 2018-10-10
WO2012170807A2 (en) 2012-12-13
US20160297872A1 (en) 2016-10-13
HUE038509T2 (hu) 2018-10-29
EP2718320B1 (en) 2018-01-10
HRP20180458T1 (hr) 2018-06-29
US20190322726A1 (en) 2019-10-24
KR20140034877A (ko) 2014-03-20
MX349886B (es) 2017-08-17
RS57024B1 (sr) 2018-05-31
AU2012267732A1 (en) 2014-01-09
NZ618266A (en) 2016-04-29
RU2018102606A (ru) 2019-02-22
AU2019257355A1 (en) 2019-11-14
ES2664972T3 (es) 2018-04-24
CN103974975A (zh) 2014-08-06
JP6420813B2 (ja) 2018-11-07
RU2708977C2 (ru) 2019-12-12
RU2018102606A3 (sl) 2019-02-22
BR112013031485B1 (pt) 2022-06-14
JP2017074057A (ja) 2017-04-20
PL2718320T3 (pl) 2018-06-29
BR112013031485A8 (pt) 2022-05-17
CY1120557T1 (el) 2019-07-10
JP6058645B2 (ja) 2017-01-11
CA2838211C (en) 2023-08-01
HK1257190A1 (zh) 2019-10-18
CA2838211A1 (en) 2012-12-13
KR102111171B1 (ko) 2020-05-14
EP2718320A4 (en) 2015-03-04
AU2017204447B2 (en) 2019-08-01
PT2718320T (pt) 2018-03-26
US10370436B2 (en) 2019-08-06
RU2014100111A (ru) 2015-07-20
LT2718320T (lt) 2018-04-10
US20140227285A1 (en) 2014-08-14
US10844114B2 (en) 2020-11-24
US20210130442A1 (en) 2021-05-06
AU2017204447A1 (en) 2017-07-20
JP2014519334A (ja) 2014-08-14
US9403901B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
SI2718320T1 (sl) Molekule, ki vežejo anti-Pseudomonas psl in njihova uporaba
NZ721678A (en) Antibody molecules to pd-1 and uses thereof
HRP20201370T1 (hr) Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
MY186351A (en) Multispecific antibodies
SI2771031T1 (sl) Humanizirana protitelesa, ki prepoznajo alfa-sinuklein
JP2017052784A5 (sl)
RU2014149553A (ru) Биспецифические анти-vegf/анти-ang-2 антитела
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ598063A (en) Gram-positive bacteria specific binding compounds
RU2017125758A (ru) Антитела к с5 и способы их применения
NZ607510A (en) Anti-il-1 beta antibodies and methods of use
PE20170071A1 (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas
JP2014509510A5 (sl)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
SI2542257T1 (sl) Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI)
SI2780368T1 (sl) Sestavki in postopki za povečanje mišične mase in mišične moči s specifičnim antagoniziranjem gdf8 in/ali aktivinom a
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ715896A (en) Humanized or chimeric cd3 antibodies
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
WO2008019061A3 (en) Anti-il-6 monoclonal antibodies and uses thereof
RU2009118621A (ru) Агонистические антитела против notch3 и их применение для лечения ntch3-ассоциированных заболеваний
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration